Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Rifaximin × Clear all

Phase

Status

Terminated 1 Recruiting 1 Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Cyclophosphamide 1326 Cisplatin 1259 Paclitaxel 1184 Radiotherapy 1183 Carboplatin 1111 Gemcitabine 1090 Docetaxel 1011 Bevacizumab 958 Fluorouracil 804 Doxorubicin 715 Capecitabine 670 Dexamethasone 669 Rituximab 665 Oxaliplatin 632 Etoposide 601 pembrolizumab 581 Irinotecan 575 Filgrastim 554 Leucovorin 523 Cytarabine 518 Nivolumab 500 Vincristine 457 Prednisone 428 Bortezomib 427 Cetuximab 421 Erlotinib Hydrochloride 420 Trastuzumab 417 Surveys and Questionnaires 401 Methotrexate 385 Lenalidomide 375

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00967096 2013-11-27

Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)

Emory University

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡